Actavis takes over global rights for Valeant’s Metronidazole 1.3% vaginal gel antibiotic
Metronidazole 1.3% vaginal gel antibiotic development product is a topical antibiotic developed for the treatment of bacterial vaginosis. The agreement includes upfront and certain milestone payments in addition
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.